Sign in Sign up for free

Last updated: 4 June 2024 at 5:20pm EST

Alexandra Glucksmann Net Worth




The estimated Net Worth of Alexandra Glucksmann is at least $1.82 Million dollars as of 15 March 2017. Alexandra Glucksmann owns over 1,000 units of Regenxbio Inc stock worth over $1,509,795 and over the last 8 years he sold RGNX stock worth over $0. In addition, he makes $312,827 as Independent Director at Regenxbio Inc.

Alexandra Glucksmann RGNX stock SEC Form 4 insiders trading

Alexandra has made over 4 trades of the Regenxbio Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 1,000 units of RGNX stock worth $650 on 15 March 2017.

The largest trade he's ever made was exercising 6,000 units of Regenxbio Inc stock on 15 February 2017 worth over $3,900. On average, Alexandra trades about 818 units every 19 days since 2016. As of 15 March 2017 he still owns at least 118,788 units of Regenxbio Inc stock.

You can see the complete history of Alexandra Glucksmann stock trades at the bottom of the page.





Alexandra Glucksmann biography

DR. Alexandra Glucksmann Ph.D. serves as Independent Director of the Company. Dr. Glucksmann has been a Director since May 2018. Dr. Glucksmann has served as the President and Chief Executive Officer of Cedilla Therapeutics, Inc., a privately held biotechnology company, since April 2018. From October 2017 to March 2018, Dr. Glucksmann was an Entrepreneur-in-Residence at Third Rock Ventures, LLC, a privately held healthcare venture firm, where she focused on company formation. She was also a founding employee of Editas Medicine, Inc., a publicly held biotechnology company, and served as its Chief Operating Officer from October 2013 to March 2017. Prior to that, Dr. Glucksmann was a founding employee of Cerulean Pharma Inc., a publicly held biotechnology company, and served as its Senior Vice President of research and business operations from September 2006 to June 2013. Dr. Glucksmann has served as a director at Scenic Biotech BV, a privately held biotechnology company, since September 2017. From August 2006 to May 2015, she served as a director at Taconic Biosciences, Inc. Dr. Glucksmann received a B.S. in Bacteriology from the University of Wisconsin-Madison and a Ph.D. in Molecular Genetics and Cell Biology from the University of Chicago, and she completed her postdoctoral fellowship at the Massachusetts Institute of Technology. Dr. Glucksmann’s qualifications to continue to serve as a member of the Board include her extensive experience in senior management positions at biotechnology companies, particularly her experience in the formation and development of biotechnology companies.

What is the salary of Alexandra Glucksmann?

As the Independent Director of Regenxbio Inc, the total compensation of Alexandra Glucksmann at Regenxbio Inc is $312,827. There are 17 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.



What's Alexandra Glucksmann's mailing address?

Alexandra's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.

Insiders trading at Regenxbio Inc

Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas, and Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.



What does Regenxbio Inc do?

regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.



What does Regenxbio Inc's logo look like?

Regenxbio Inc logo

Complete history of Alexandra Glucksmann stock trades at Editas Medicine Inc and Regenxbio Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
15 Mar 2017 EDIT Editas Medicine Inc Alexandra Glucksmann
Chief Operating Officer
 Option 1,000 $0.65 $650
15 Mar 2017
118,788 ↗
15 Feb 2017 EDIT Editas Medicine Inc Alexandra Glucksmann
Chief Operating Officer
 Option 6,000 $0.65 $3,900
15 Feb 2017
123,788 ↗
23 Aug 2016 EDIT Editas Medicine Inc Alexandra Glucksmann
Chief Operating Officer
 Option 1,000 $0.65 $650
23 Aug 2016
118,788 ↗
23 Aug 2016 EDIT Editas Medicine Inc Alexandra Glucksmann
Chief Operating Officer
 Option 1,000 $0.65 $650
23 Aug 2016
118,788 ↗


Regenxbio Inc executives and stock owners

Regenxbio Inc executives and other stock owners filed with the SEC include: